Skip to main content
SpringerLink
Log in

Vaxelis® (DTaP5-HB-IPV-Hib vaccine) as primary and booster vaccination in infants and toddlers: a profile of its use

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Vaxelis® (DTaP5-HB-IPV-Hib vaccine) is a fully liquid, ready-to-use, hexavalent vaccine containing diphtheria toxoid, tetanus toxoid, five acellular pertussis antigens, hepatitis B surface antigen, inactivated poliovirus and the Haemophilus influenzae type b capsular polysaccharide polyribosylribitol phosphate conjugated to the outer membrane protein complex of Neisseria meningitidis. In pivotal clinical studies in infants and toddlers, Vaxelis® was highly immunogenic for all its component toxoids/antigens when administered by three different schedules. In general, primary endpoints of seroprotection or vaccine response rates with Vaxelis® met the predefined acceptability criteria and were noninferior to those with comparator vaccines (Infanrix® hexa or Pentacel® + Recombivax HB®). Vaxelis® can be coadministered with a number of common childhood vaccines. In clinical studies, Vaxelis® was generally well tolerated with a tolerability profile similar to that of the comparator vaccines. Available clinical data indicate that Vaxelis® is a new hexavalent vaccine option for immunization against several serious childhood infectious diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. European Centre for Disease Prevention and Control. Vaccine schedule. 2016. http://vaccine-schedule.ecdc.europa.eu. Accessed 3 Mar 2017.

  2. Skibinski DAG, Baudner BC, Singh M, et al. Combination vaccines. J Global Infect Dis. 2011;3(1):63–72.

    Article  Google Scholar 

  3. Vaxelis®: summary of product characteristics. London: European Medicines Agency; 2017.

  4. McCormack PL. DTaP-IPV-Hep B-Hib vaccine (Hexaxim®): a review of its use in primary and booster vaccination. Paediatr Drugs. 2013;15(1):59–70.

    Article  PubMed  Google Scholar 

  5. Hexacima®: summary of product characteristics. London: European Medicines Agency; 2017.

  6. Dhillon S. DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa™): a review of its use as primary and booster vaccination. Drugs. 2010;70(8):1021–58.

    Article  CAS  PubMed  Google Scholar 

  7. Infanrix hexa®: summary of product characteristics. London: European Medicines Agency; 2017.

  8. Vaxelis®: Committee for Medicinal Products for Human Use assessment report. London: European Medicines Agency; 2015.

  9. Vesikari T, Becker T, Vertruyen AF, et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 3, 4, and 12 months. Pediatr Infect Dis J. 2017;36(2):209–15.

    Article  PubMed  Google Scholar 

  10. Silfverdal SA, Icardi G, Vesikari T, et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11–12 months. Vaccine. 2016;34(33):3810–6.

    Article  CAS  PubMed  Google Scholar 

  11. Marshall GS, Adams GL, Leonardi ML, et al. Immunogenicity, safety, and tolerability of a hexavalent vaccine in infants. Pediatrics. 2015;136(2):e323–32.

    Article  PubMed  Google Scholar 

  12. Block SL, Klein NP, Sarpong K, et al. Lot-to-lot consistency, safety, tolerability, and immunogenicity of an investigational hexavalent vaccine in US infants. Pediatr Infect Dis J. 2017;36(2):202–8.

    Article  PubMed  Google Scholar 

  13. Oliver JL, Snape MD, Heath PT, et al. Investigational hexavalent vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during primary series [abstract no. ESPID-0936]. In: 33rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). 2015.

  14. US National Institutes of Health. ClinicalTrials.gov (NCT01337167). 2016. https://clinicaltrials.gov. Accessed 1 Mar 2017.

  15. US National Institutes of Health. ClinicalTrials.gov (NCT01340937). 2016. https://clinicaltrials.gov. Accessed 1 Mar 2017.

  16. Tapiero B, Halperin SA, Dionne M, et al. Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study. Pediatr Infect Dis J. 2013;32(1):54–61.

    Article  PubMed  Google Scholar 

  17. Halperin SA, Tapiero B, Dionne M, et al. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2014;33(1):73–80.

    Article  PubMed  Google Scholar 

  18. Block SL, Marshall GS, Petrecz M, et al. Immunogenicity and safety of an investigational hexavalent vaccine against diphtheria, tetanus, pertussis (DTaP5), polio (IPV), H. Influenzae type b (Hib; PRP-OMPC), and hepatitis B (HepB) administered concomitantly with RV5 and PCV-13 in US Infants [slides]. In: American Academy of Pediatrics (AAP) National Conference & Exhibition. 2015.

  19. Syed YY. DTaP5-HB-IPV-Hib vaccine (Vaxelis®): a review of its use in primary and booster vaccination. Paediatr Drugs. 2017;19(1):69–80.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The manuscript was adapted from Pediatric Drugs 2017;19(1):69–90 [19], and was reviewed by: G. Gabutti, Department of Medical Sciences, University of Ferrara, Ferrara, Italy; G. Icardi, Department of Health Sciences, University of Genoa, Genoa, Italy; Y. Kino, Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan. During the peer review process, the manufacturer of Vaxelis® was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Gillian M. Keating, Katherine A. Lyseng-Williamson & Yahiya Y. Syed

Authors
  1. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yahiya Y. Syed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

G.M. Keating, K.A. Williamson-Lyseng and Y.Y. Syed were/are salaried employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Keating, G.M., Lyseng-Williamson, K.A. & Syed, Y.Y. Vaxelis® (DTaP5-HB-IPV-Hib vaccine) as primary and booster vaccination in infants and toddlers: a profile of its use. Drugs Ther Perspect 33, 208–213 (2017). https://doi.org/10.1007/s40267-017-0400-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-017-0400-3

Keywords

Search

Navigation